Please assess the completion status of the following clinical trial:

Trial Title: EMPOWIR:Enhance the Metabolic Profile of Women With Insulin Resistance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy, non-diabetic women with ≥20 pound weight gain since their twenties~2. Age: 35-55~3. Peri-menopausal or postmenopausal status~4. Body Mass Index (BMI) 25-35 kg/m2~5. Either:~   1. a single blood pressure recording ≥135/85 or the use of blood pressure medication OR~  2. HDL≤50mg/dl or triglycerides ≥150 mg/dl or the use of lipid modifying medication~6. Area-under-the-curve (AUC-)insulin level\>100mcgU/ml along with normal fasting (≤100 mg/dl) \& postprandial ((≤200 mg/dl) glucose determinations following a 75-gram standard oral glucose tolerance test.~   -~Exclusion Criteria:~1. known diabetes, fasting blood sugar ≥100 mg/dl or HbA-1-C≥6.0%~2. known hepatic disease or ALT\>40~3. known renal disease or creatinine ≥ 1.4~4. known severe pulmonary disease~5. chronic acidosis of any etiology~6. Congestive heart failure (NYS Category 1), treated or untreated~7. Cancer - active within 5 years~8. current alcoholism or other substance abuse~9. co-morbid psychiatric disorder, which in the opinion of the screening physician would require concomitant psychotherapy as part of obesity management~10. currently untreated thyroid abnormality (TSH≤0.2 or ≥4mIU/L)~11. pregnancy or contemplation of pregnancy~12. use of TZD or metformin within the past year~13. allergy to TZD or biguanide~14. use of FDA approved or alternate obesity agent within 6 months of the study~15. history of pseudotumor cerebri~16. other impairment, such as a history of medication noncompliance, which in the judgment of the screening clinician, would preclude active study participation.~17. history of known or suspected heart disease

- Gender: FEMALE
- Minimum Age: 35 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- A: Study diet (Type: PLACEBO_COMPARATOR): EMPOWIR dietary intervention food exchange program; 40-45% carbohydrates, 35-40% protein, and 20% fat AND 4 week dosage escalation of placebo metformin, 500 mg/day to a total dose of 2000mg/day; starting dose of placebo rosiglitazone 2mg/day added at weeks 3 and weeks 4 to a total dose of 4 mg/day.
- B: Study diet plus Metformin (Type: ACTIVE_COMPARATOR): Metformin and Rosiglitazone Placebo~EMPOWIR dietary intervention food exchange program; 40-45% carbohydrates, 35-40% protein, and 20% fat AND 4 week dosage escalation of metformin, 500 mg/day to a total dose of 2000mg/day; starting dose of placebo rosiglitazone 2mg/day added at weeks 3 and weeks 4 to a total dose of 4 mg/day.
- C: Study diet plus metformin and avandia (Type: ACTIVE_COMPARATOR): Metformin and Rosiglitazone~EMPOWIR dietary intervention food exchange program; 40-45% carbohydrates, 35-40% protein, and 20% fat AND 4 week dosage escalation of metformin, 500 mg/day to a total dose of 2000mg/day; starting dose of rosiglitazone 2mg/day added at weeks 3 and weeks 4 to a total dose of 4 mg/day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete